Navigation Links
Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
Date:5/2/2012

OXFORD, England, May 2, 2012 /PRNewswire/ --

Oxford BioTherapeutics (OBT) today announces the appointment of Dr Esteban Pombo-Villar as Chief Operations Officer (COO) of the OBT group. In this position he will lead the company's newly created clinical development operations based in Basel, Switzerland.  The establishment of a dedicated development operation represents a key milestone in OBT's global expansion as it progresses its most advanced therapeutic antibody and antibody drug conjugate (ADC) oncology programs into clinical development.  Dr Pombo-Villar will also become an executive member of OBT's Board.

Prior to joining OBT, Dr Pombo-Villar was at Novartis for over 20 years, the last 12 years of which he focused on all aspects of creating and managing alliances. Most recently he was Head of Alliance Management at the Novartis Institute for Biomedical Research (NIBR), responsible for alliances up to proof-of-concept in man.  He has a PhD in organic chemistry and completed postdoctoral studies at the ETH in Zurich before joining Sandoz Neuroscience Research in Basel in 1988.  At Sandoz he worked on drug discovery projects as well as leading collaborative projects investigating the potential of emerging technologies. Dr Pombo-Villar is a Fellow of the Royal Society of Chemistry.

Dr Pombo-Villar commented, "I am delighted to join OBT at this exciting stage in the company's development as it transitions into a clinical development organisation. This is a compelling opportunity to directly impact the future treatment of cancer by helping to shape the direction and success of OBT as an emerging leader in the field."

Dr Christian Rohlff, CEO of OBT, commented, "I am very pleased to welcome Esteban to OBT and to officially open our new clinical operations site in Basel, Switzerland.  Esteban's extensive executive leadership experience in the industry will bring considerable value to OBT as we advance our highly promising lead programs into the clinic."

OBT's clinical development operation in Basel, Switzerland, represents an important site for the company's future expansion, in addition to its corporate headquarters and discovery labs located in Oxford, UK, and R&D facility in San Jose, California. In 2011, OBT made significant progress in the ADC field, announcing a collaboration with Seattle Genetics, Inc. for the discovery of multiple ADC programs for cancer and an out-licensing deal with Sanofi for a preclinical ADC program for the treatment of solid tumours.

About Oxford BioTherapeutics

Oxford BioTherapeutics (OBT) is a leading international biotechnology company focused on delivering innovative and cost-effective first-in-class medicines to fulfil major unmet patient needs in the field of cancer. OBT is developing cutting-edge antibody-based cancer medicines, with integrated diagnostics, against novel targets that it has discovered through its unique OGAP® proteomic database. OBT has access to the most advanced antibody technologies and expertise through its partnerships with many of the world leaders in antibody development, including Seattle Genetics, BMS (Medarex), Amgen, Alere (formerly Biosite) and BioWa, and through its development alliances with GlaxoSmithKline and Sanofi. OBT's diagnostic collaboration with Alere also provides the opportunity to develop tailored diagnostics for OBT's therapeutic products. These partnerships have enabled OBT to convert its world leading capabilities in the discovery of novel oncology targets into a highly attractive pipeline of therapeutic antibodies.

For further information, please see http://www.OxfordBioTherapeutics.com

OBT Contact Information:
Chief Executive Officer:    
Christian Rohlff, Ph.D.    
+44(0)1235-861770    
E-mail    
cr@oxbt.co.uk
       
Media enquiries/Citigate:    
David Dible    
+44(0)207-638-9571    
E-mail    
david.dible@citigatedr.co.uk


'/>"/>
SOURCE Oxford BioTherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
2. Oxford Finance Corporation Closes $25 Million Credit Facility with EUSA Pharma
3. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets
4. Oxford Finance Corporation and United Orthopedic Group, Inc. Close $20 Million Credit Facility
5. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
6. Oxford Finance Corporation Hires Debbie Baker to Support Life Science Business Development in Western North America
7. Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation
8. ICAP Ocean Tomo Announces Four Patent Sets From Oxford Instruments - Each Represents an Important Advancement in Technology
9. Oxford BioTherapeutics Licenses BioWas POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer
10. Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp.
11. Oxford BioMedica Announces Ocular Programme Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... 2017 Acute, Chronic and Prophylaxis GVHD ... a CAGR of 7% from 2016-2021 and CAGR of 3% from 2021-2027. ... 2016 to 2027. The market is estimated at $0.36bn in 2016, $0.51bn ... ... how you can exploit the future business opportunities emerging in this sector. ...
(Date:2/19/2017)... , Feb. 19, 2017  nThrive™, an ... cycle portfolio and thought leadership at the 2017 ... a category leader award from KLAS. ... discussion focused on how market trends shape the ... particularly a sophisticated, comprehensive Patient Access solution. The ...
(Date:2/19/2017)... ORLANDO, Fla. , Feb. 18, 2017 ... that positive Phase 1 clinical data for Nektar,s lead ... (RCC) were presented at ASCO GU 2017.  NKTR-214 is ... T cells and Natural Killer (NK) cell abundance directly ... on these immune cells.  The results were presented by ...
Breaking Medicine Technology:
(Date:2/19/2017)... ... February 19, 2017 , ... ... home healthcare, will join forces with Healthwise ® at HIMSS 2017 ... the industry leader in evidence-based health education, technology and services, will demonstrate a ...
(Date:2/18/2017)... , ... February 17, 2017 , ... ... drvallecillos.com , Beverly Hills plastic surgeon Dr. Glenn Vallecillos ... , Dr. Vallecillos says, "Traditionally, plastic surgery has been centered around that idea ...
(Date:2/17/2017)... ... 2017 , ... Smiles by Seese is a comprehensive family dental practice ... leads the practice as a skilled and highly credentialed dentist who is qualified to ... patients of all ages with excellence in general, restorative, and cosmetic dentistry . ...
(Date:2/17/2017)... ... 2017 , ... For the first time, International Scholarship and ... floor for the 2017 HIMSS Conference & Exhibition at the Orange ... than 40,000 healthcare industry professionals are expected at the conference, where they will ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... has been named a finalist in the 8th Annual DecisionHealth Platinum Awards in ... delivery system. Qualis Health’s work is recognized across multiple award categories, highlighting four ...
Breaking Medicine News(10 mins):